Overview A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer. Phase: Phase 3 Details Lead Sponsor: AbbottTreatments: AtrasentanHormones